Delving into the Latest Updates on Rosiglitazone Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

太罗

Target

PPARγ

Mechanism

PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists), Insulin sensitizers

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Taiji Group Co. Ltd.

Active Organization

Taiji Group Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (14 Sep 2004),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H19N3O3S

InChIKeyYASAKCUCGLMORW-UHFFFAOYSA-N

CAS Registry122320-73-4

View All Structures (2)

The aim of this study was to prepare the rosiglitazone sodium enteric-coated tablets and investigate its release rate. The rosiglitazone sodium enteric-coated tablet was prepared by single punch tablet press using substituted hydroxypropyl cellulose and polyvinylpyrrolidone (PVP). The release rate from the enteric-coated tablet of rosiglitazone sodium was evaluated. The release rate study showed that few rosiglitazone sodium was released from enteric coated formulation within 2 h in simulated gastric juice, while it released more than 80% of the labeled amount in 30 min in simulated intestinal juice. The preparing method of rosiglitazone sodium enteric-coated tablets was simple and had a good reproducibility. The release condition and determined methods could be used for the routine determinations of rosiglitazone sodium enteric-coated tablets.

01 Mar 2010·Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

[Protective effect of fibroblast growth factors-21 and rosiglitazone sodium on palmitic acid-induced apoptosis in HIT-T15 cells].

Article

Author: Wang, Chun ; Zhang, Mei ; Zhang, Lin ; Xiong, Zhong-yun ; An, Zhen-mei

OBJECTIVETo investigate the protective effect of fibroblast growth factors-21 (FGF-21) and rosiglitazone sodium (RO) on palmitic acid-induced apoptosis in HIT-T15 cells.METHODS(1) HIT-T15 cells were treated with 0.25 mmol/L, 0.50 mmol/L and 1.00 mol/L of palmitic acid for 24 hours. (2) FGF-21 [12.50 nmol/L (A), 25.00 nmol/L(B), 50.00 nmol/L(C)], or 1 micromol/L of RO, or a combination of the two were added to the cells treated with 0.50 mmol/L of palmitic acid. Cell apoptosis was measured by flow cytometer. Phosphorylation-c-Jun N-terminal kinases (p-JNK) was detected by immuocytochemistry and Western blot.RESULTS(1) The cells treated with palmitic acid has significantly higher apoptosis rates than controls (P < 0.05). (2) FGF-21 reduced apoptosis rates induced by palmitic acid (P < 0.05). But the apoptosis rates remained higher than controls (P < 0.05). A combination of FGF-21 and RO further reduced the apoptosis rates compared with FGF-21 alone (P < 0.05). (3) The cells treated with palmitic acid had higher expression of p-JNK than controls (P < 0.05). FGF-21 and a combination of FGF-21 and RO reduced the expression of p-JNK in cells treated with palmitic acid (P < 0.05).CONCLUSION(1) Palmitic acid induces apoptosis in HIT-T15 cells in a dose dependent way. (2) The expression of p-JNK induced by palimitic acid is reduced by FGF-21 and the combination of FGF-21 and RO.

100 Deals associated with Rosiglitazone Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10BG02	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	CN	Taiji Group Co. Ltd.	14 Sep 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00577590 (T2DM, CTgov)	Not Applicable	Diabetes Mellitus, Type 2	78	Lovaza+Metformin (Metformin and Lovaza)	mxfjqxwyvc(vfyenwinni) = eflpahfnyw wpwqsuznpd (lrmkgklvhf, tskvlgfjld - wacwbpcbpc) View more	-	31 Aug 2018
				Rosiglitazone+Metformin (Metformin and Rosiglitazone)	mxfjqxwyvc(vfyenwinni) = zctefckgqi wpwqsuznpd (lrmkgklvhf, szcybudoyh - acfmeqlmyt) View more
NCT00186537 (CTgov)	Not Applicable	Hypertriglyceridemia \| Insulin Resistance	47	fenofibrate (Fenofibrate)	aoipzfscct(ssbapvqtad) = kaglyvsjbo dkkjmiedyj (aemghoryly, frcdzzxhiq - mhdeqyndht) View more	-	05 May 2016
				Rosiglitazone (Rosiglitazone)	aoipzfscct(ssbapvqtad) = azufdqitae dkkjmiedyj (aemghoryly, dvtukfixyz - jznswatdnd) View more
NCT00785213 (CTgov)	Phase 1	-	23	Rosiglitazone 4 mg Tablets	xkqzucgbgy(iaghfgctom) = lxkmrbvbwq rxbwrzjlio (opwwgqqnjm, qnslmnlqoe - nvhowhwxhl) View more	-	26 Nov 2009
NCT00095654 (DREAM, Pubmed \| Diabetes Care)	Phase 3	Glucose Intolerance	-	Ramipril	(hlqbowbezl) = Rosiglitazone increased heart failure (0.53 vs. 0.08%) buxkmcwyya (qpbmdkolbf )	-	01 May 2008
				Rosiglitazone
NCT00095654 (Pubmed \| Lancet)	Phase 3	Glucose Intolerance	5,269	Rosiglitazone	joexktgnpn(mxkgqxsjxf): hazard ratio = 0.4 (95% CI, 0.35 - 0.46), P-Value = <0.0001 View more	Positive	23 Sep 2006
				Placebo